WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.

Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates

CLSI SIDP 2024 Webinar

Breaking Bad Bacteria: Mastering the 2024 CLSI Antimicrobial Susceptibility Testing Updates

Date: Wednesday, August 7, 2024 | 1:00 PM – 2:30 PM ET / 12:00 PM – 1:30 PM CT 

This annual webinar is a collaboration between Clinical and Laboratory Standards Institute (CLSI), Society of Infectious Disease Pharmacists (SIDP), and the American College of Clinical Pharmacists (ACCP). It will provide updates on the latest breakpoint recommendations from CLSI M100 | Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition, and offers practical strategies on incorporating those changes into clinical practice. Speakers will address the importance of partnerships between pharmacists and laboratory professionals on effective implementation of updates to enhance clinical practice. Audience polling will be included throughout, with an opportunity for Q&A at the end. 

CLSI members can register for free by signing into their CLSI account. SIDP and ACCP ID PRN members, please register on SIDP's website.  

Price: Free for CLSI members, $15 for nonmembers 

Target Audience: This activity was planned to meet the educational needs of pharmacists and laboratory Professionals. 

Navaneeth Narayanan, PharmD, MPH, BCIDP, Clinical Associate Professor 
Rutgers University 

Virginia M. Pierce, MD, FIDSA, Clinical Associate Professor of Pathology and Pediatrics (Pediatric Infectious Diseases)
University of Michigan Medical School 

Earn 1.5 P.A.C.E.®️ credits. 

List Price:
Log in/sign up to see price and add to cart


Date of Webinar: August 7, 2024

CLSI SIDP 2024 Webinar Additional Details

Learning Objectives

  • Summarize highlights from CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition standards for antimicrobial susceptibility testing (AST) and reporting.
  • Examine nuances that may be encountered when performing (AST) for carbapenem-resistant bacteria.
  • Evaluate species-specific guidance for AST of Staphylococcus sp. and ceftriaxone dosing guidance for methicillin-susceptible Staphylococcus aureus.
  • Discuss the revised breakpoints, reporting, and treatment recommendations for Stenotrophomonas maltophilia

CLSI is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.